相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antibody-based methods for the measurement of α-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study
Brit Mollenhauer et al.
JOURNAL OF NEUROCHEMISTRY (2019)
Cerebrospinal Fluid Total and Phosphorylated -Synuclein in Patients with Creutzfeldt-Jakob Disease and Synucleinopathy
Matthias Schmitz et al.
MOLECULAR NEUROBIOLOGY (2019)
How is alpha-synuclein cleared from the cell?
Leonidas Stefanis et al.
JOURNAL OF NEUROCHEMISTRY (2019)
Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease
Courtney L. Sutphen et al.
ALZHEIMERS & DEMENTIA (2018)
Extracellular α-synuclein levels are regulated by neuronal activity
Kaoru Yamada et al.
MOLECULAR NEURODEGENERATION (2018)
Cerebrospinal fluid NFL in the differential diagnosis of parkinsonian disorders: A meta-analysis
Fangfang Ge et al.
NEUROSCIENCE LETTERS (2018)
Evolution of cerebrospinal fluid total alpha-synuclein in Parkinson's disease
Marthe Gurine Forland et al.
PARKINSONISM & RELATED DISORDERS (2018)
Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC
Bradley R. Groveman et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2018)
Parkinson's Disease Is Not Simply a Prion Disorder
James Surmeier et al.
JOURNAL OF NEUROSCIENCE (2017)
Diagnostic Utility of Cerebrospinal Fluid α-Synuclein in Parkinson's Disease: A Systematic Review and Meta-Analysis
Paolo Eusebi et al.
MOVEMENT DISORDERS (2017)
Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls
Brit Mollenhauer et al.
NEUROLOGY (2017)
Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid
Mohammad Shahnawaz et al.
JAMA NEUROLOGY (2017)
Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort
Danna Jennings et al.
JAMA NEUROLOGY (2017)
Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease
Chelsea Caspell-Garcia et al.
PLOS ONE (2017)
Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels
Laura Ibanez et al.
BMC NEUROLOGY (2017)
Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI)
Mike A. Nalls et al.
MOVEMENT DISORDERS (2016)
Value of cerebrospinal fluid -synuclein species as biomarker in Parkinson's diagnosis and prognosis
Lucilla Parnetti et al.
BIOMARKERS IN MEDICINE (2016)
Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease
Sara Hall et al.
MOVEMENT DISORDERS (2016)
Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression
Nour K. Majbour et al.
MOVEMENT DISORDERS (2016)
Monitoring of 30 marker candidates in early Parkinson disease as progression markers
Brit Mollenhauer et al.
NEUROLOGY (2016)
Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorder
L. M. Chahine et al.
PARKINSONISM & RELATED DISORDERS (2016)
Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies
Graham Fairfoul et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease
Yaroslau Compta et al.
JOURNAL OF NEUROLOGY (2015)
Cerebrospinal Fluid α-Synuclein Predicts Cognitive Decline in Parkinson Disease Progression in the DATATOP Cohort
Tessandra Stewart et al.
AMERICAN JOURNAL OF PATHOLOGY (2014)
Low clinical diagnostic accuracy of early vs advanced Parkinson disease Clinicopathologic study
Charles H. Adler et al.
NEUROLOGY (2014)
Lentivirus Mediated Delivery of Neurosin Promotes Clearance of Wild-type α-Synuclein and Reduces the Pathology in an α-Synuclein Model of LBD
Brian Spencer et al.
MOLECULAR THERAPY (2013)
Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series
Carlos H. Schenck et al.
SLEEP MEDICINE (2013)
Normative EMG Values during REM Sleep for the Diagnosis of REM Sleep Behavior Disorder
Birgit Frauscher et al.
SLEEP (2012)
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study (vol 10, pg 230, 2011)
B. Mollenhauer et al.
LANCET NEUROLOGY (2011)
The Parkinson Progression Marker Initiative (PPMI)
Kenneth Marek et al.
PROGRESS IN NEUROBIOLOGY (2011)
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study
Brit Mollenhauer et al.
LANCET NEUROLOGY (2011)
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease
Zhen Hong et al.
BRAIN (2010)
Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson's Disease
Claire L. Tomlinson et al.
MOVEMENT DISORDERS (2010)
CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease
A. Siderowf et al.
NEUROLOGY (2010)
Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale Presentation and Clinimetric Testing Results
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2008)
GATA transcription factors directly regulate the Parkinson's disease-linked gene α-synuclein
Clemens R. Scherzer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The REM sleep behavior disorder screening questionnaire -: A new diagnostic instrument
Karin Stiasny-Kolster et al.
MOVEMENT DISORDERS (2007)
REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia
M. Vendette et al.
NEUROLOGY (2007)
Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease
Takahiko Tokuda et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications
EP Diamandis et al.
CLINICAL BIOCHEMISTRY (2000)
分享论文
